# Evaluation of a Genetically Determined Personalized Approach in Prescribing Biologically Active Substances in Patients With Elevated Blood Homocysteine Levels.

> **NCT06264570** · NA · RECRUITING · sponsor: **S.LAB (SOLOWAYS)** · enrollment: 111 (estimated)

## Conditions studied

- Hyperhomocysteinemia

## Interventions

- **DIETARY_SUPPLEMENT:** B-TMG supplementation
- **DIETARY_SUPPLEMENT:** B-SAM supplementation
- **OTHER:** B-TMG placebo
- **OTHER:** B-SAM placebo

## Key facts

- **NCT ID:** NCT06264570
- **Lead sponsor:** S.LAB (SOLOWAYS)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-23
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-10-30
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06264570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06264570, "Evaluation of a Genetically Determined Personalized Approach in Prescribing Biologically Active Substances in Patients With Elevated Blood Homocysteine Levels.". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06264570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*